Phaseline

Companies › Medley Therapeutics

Medley Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
YAP101 (AAV9-Sav-shRNA)
AAV9-delivered short hairpin RNA targeting YAP1 to promote cardiac regeneration
YAP1Phase 1Heart Failure With Reduced Ejection FractionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06831825YAP101 (AAV9-Sav-shRNA)Phase 1Heart Failure With Reduced Ejection FractionCardiovascularDec 2026

Targets

YAP1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.